Investigational drug · Phase 2
ETH47
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Asthma (Diagnosis).
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
2
Any phase or sponsor naming "ETH47"
First trial start
2025
Jun 24, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ETH47", any sponsor or status.
Conditions studied
As listed on its trial records.
- Asthma (Diagnosis)
Approved drugs for the same conditions: Asthma · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "ETH47" as an intervention, largest first.
Ethris GmbHIndustry
NCT07055321 · 73 participants · Start Nov 29, 2023 · Primary completion Jul 8, 2024
Drug: ETH47; ETH47 and 7 more · For: Healthy Subjects
Sites: Merthyr Tydfil, United Kingdom
Ethris GmbHIndustry
NCT07059767 · 50 participants · Start Jun 24, 2025 · Primary completion Sep 1, 2026
Drug: ETH47; Placebo · For: Asthma (Diagnosis)
Sites: London, United Kingdom; Manchester, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
- Mucosal IFNλ1 mRNA-based immunomodulation effectively reduces SARS-CoV-2 induced mortality in mice.
Macht A, Huang Y, Reinert LS, et al. · EMBO Rep 2024
Also in development for Asthma (Diagnosis)
- KT-621Phase 23 trials
Kymera Therapeutics, Inc. · Eosinophilic Asthma, Atopic Dermatitis, Asthma (Diagnosis)
- linvemastatFP-020Phase 21 trial
Foresee Pharmaceuticals Co., Ltd. · Asthma (Diagnosis), Pulmonary Function, Moderate-to-Severe Asthma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.